Horizon Discovery Group plc Total Voting Rights (9904J)
December 10 2018 - 6:17AM
UK Regulatory
TIDMHZD
RNS Number : 9904J
Horizon Discovery Group plc
10 December 2018
10 December 2018
Horizon Discovery Group plc
Total Voting Rights
In accordance with Disclosure and Transparency Rule 5.6.1
Horizon Discovery Group plc (the "Company") advises that:
As at 30 November 2018, the Company's issued share capital
consisted of 150,333,908 ordinary shares of 1p each with voting
rights. The Company does not hold any ordinary shares in
Treasury.
The total number of voting rights in the Company is therefore
150,333,908.
The above figure (150,333,908) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Horizon Discovery Group plc under the FCA's
Disclosure and Transparency Rules.
ENDS
For further information, please contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
delivers inspired cell solutions using its translational genomics
platform, a highly precise and flexible suite of DNA editing (rAAV,
ZFN, CRISPR and Transposon) and modulation (RNAi, cDNA and ORF)
tools for research and clinical applications that advance human
health. Horizon's platforms and capabilities enable researchers to
alter almost any gene or modulate its function in human or
mammalian cell lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalized molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRGGGAGPUPRGPU
(END) Dow Jones Newswires
December 10, 2018 07:17 ET (12:17 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024